BEGIN:VCALENDAR
VERSION:2.0
PRODID:www.dresden-science-calendar.de
METHOD:PUBLISH
CALSCALE:GREGORIAN
X-MICROSOFT-CALSCALE:GREGORIAN
X-WR-TIMEZONE:Europe/Berlin
BEGIN:VTIMEZONE
TZID:Europe/Berlin
X-LIC-LOCATION:Europe/Berlin
BEGIN:DAYLIGHT
TZNAME:CEST
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
DTSTART:19810329T030000
RRULE:FREQ=YEARLY;INTERVAL=1;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZNAME:CET
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
DTSTART:19961027T030000
RRULE:FREQ=YEARLY;INTERVAL=1;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:DSC-8904
DTSTART;TZID=Europe/Berlin:20150310T160000
SEQUENCE:1425974496
TRANSP:OPAQUE
DTEND;TZID=Europe/Berlin:20150310T170000
URL:https://www.dresden-science-calendar.de/calendar/de/detail/8904
LOCATION:TUD CRTD\, Fetscherstraße 10501307 Dresden
SUMMARY:Scholl: Investigating the Genetics\, Structure and Function of the 
 Diseased Retina to Prepare for Clinical Trials
CLASS:PUBLIC
DESCRIPTION:Speaker: Hendrik Scholl\, Wilmer Eye Institute\, Johns Hopkins 
 University\, Baltimore\nInstitute of Speaker: \nTopics:\nBiologie\, Medizi
 n\n Location:\n  Name: TUD CRTD (CRTD\, auditorium right)\n  Street: Fetsc
 herstraße 105\n  City: 01307 Dresden\n  Phone: +49 (0)351 458 82052\n  Fa
 x: +49 (0)351 458 82059 \nDescription: Information about the speaker:Hendr
 ik Scholl is the director of the           Retinal Degenerations Clinic of
  the Retina Division and the           director of the Visual Neurophysiol
 ogy Service. He is also the           co-director of Wilmer’s newly foun
 ded Center for Stem Cells           and Ophthalmic Regenerative Medicine (
 STORM). He specializes           in medical and surgical management of ret
 inal diseases such as           age-related macular degeneration (AMD) and
  diabetic           retinopathy. He has a specific expertise in inherited 
 retinal           degenerations and uses the latest diagnostic technology 
 such           as eletroretinography\, microperimetry and high-resolution 
           imaging. Dr. Scholl’s primaryresearch interest relates to visu
 al           loss in retinal degenerations and to therapeutic measures in 
           order to rescue vision. In his leadership role of large         
   multi-center clinical studies\, he aims to develop better tools         
   to prove therapeutic efficacy for upcoming clinical trials.         Sele
 cted publications:1. Charbel Issa P\, Gillies MC\, Chew EY\, Bird AC\, Hee
 ren TF\,         Peto T\, Holz FG\, Scholl HPN (2013). Macular telangiecta
 sia type         2. Prog Retin Eye Res. 34: 49-77. 2. Weismann D\, Hartvig
 sen K\, Lauer N\, Bennett KL\, Scholl HPN\,         Charbel Issa P\, Cano 
 M\, Brandstätter H\, Tsimikas S\, Skerka C\,         Superti-Furga G\, Ha
 nda JT\, Zipfel PF\, Witztum JL\, Binder CJ         (2011) Complement fact
 or H binds malondialdehyde epitopes and         protects from oxidative st
 ress. Nature 478: 76-81.3. Charbel Issa P\, Troeger E\, Finger R\, Holz FG
 \, Wilke R\,         Scholl HPN (2010) Structure-function correlation of t
 he human         central retina. PLoS One. 22\;5(9): e12864.4. Scholl HPN\
 , Charbel Issa P\, Walier M\, Janzer S\,         Pollok-Kopp B\, Börncke 
 F\, Fritsche LG\, Chong NV\, Fimmers R\,         Wienker T\, Holz FG\, Web
 er BHF\, Oppermann M (2008) Systemic         complement activation in age-
 related macular degeneration. PLoS         ONE 3(7):e2593.5. Scholl HPN\, 
 Bellmann C\, Dandekar SS\, Bird AC\, Fitzke FW          (2004) Photopic an
 d scotopic fine matrix mapping of retinal         areas of increased fundu
 s autofluorescence in patients with         age-related maculopathy. Inves
 t Ophthalmol Vis Sci 45:574-583.
DTSTAMP:20260626T001949Z
CREATED:20150227T075013Z
LAST-MODIFIED:20150310T080136Z
END:VEVENT
END:VCALENDAR